Many drugs in development are poorly water soluble, making it difficult to create dosage forms with good bioavailability. Amorphous solid dispersion dosage forms can improve bioavailability, but designing them usually involves trial and error, and takes time.
In our recent publication, scientists at Lonza used in silico methods to predict the results of dissolution tests for different formulations of the anticancer drug acalabrutinib with remarkable accuracy. These in vitro dissolution test results were confirmed with in vivo studies. We demonstrate how this process should be applicable to other poorly soluble drugs, offering the prospect of faster, less expensive formulation development.
